Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan · Delayed Price · Currency is JPY | Market Cap | 152.61B -5.3% |
| Revenue (ttm) | 75.66B -18.9% |
| Net Income | -3.83B |
| EPS | -100.31 |
| Shares Out | 37.87M |
| PE Ratio | n/a |
| Forward PE | 81.47 |
| Dividend | 190.00 (4.71%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 187,600 |
| Average Volume | 111,475 |
| Open | 4,060.00 |
| Previous Close | 4,050.00 |
| Day's Range | 3,990.00 - 4,090.00 |
| 52-Week Range | 3,540.00 - 4,445.00 |
| Beta | 0.13 |
| RSI | 40.06 |
| Earnings Date | May 13, 2026 |
About Kaken Pharmaceutical
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger... [Read more]
Full Company ProfileFinancial Performance
In fiscal year 2025, Kaken Pharmaceutical's revenue was 94.04 billion, an increase of 30.52% compared to the previous year's 72.04 billion. Earnings were 13.95 billion, an increase of 73.77%.
Financial StatementsNews
Kaken Pharmaceutical initiated with a Neutral at UBS
UBS initiated coverage of Kaken Pharmaceutical (KKPCF) with a Neutral rating and 4,200 yen price target he firm says the company’s business stability is priced into the shares with limited